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Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL). Different survival pathways,
that is the Raf/MEK/Erk- or the p38MAPK cascade, have been suggested as downstream mediators of rituximab and may be involved
in treatment failure. Biopsies from four patients, suffering from different subtypes of CBCL, which were obtained at various time
points of relapse during or after therapy with 375mg rituximab per m
2 of body surface area, were analysed for the expression of
CD20, CD3, Ki-67, Raf-kinase inhibitory protein (RKIP) and bcl-2 by immunohistochemistry. No CD20-loss variants, that is the
suggested main tumour escape mechanism to rituximab therapy, were observed in any specimen of relapsing CBCL. Notably, the
expression of proapoptotic RKIP remained increased in these tumour samples. This was concomitated by a constant to slightly
reduced proliferation status as demonstrated by Ki-67 staining. However, relapsing CBCL exhibited a strong upregulation of the
antiapoptotic molecule bcl-2 in comparison to pretherapeutic levels. The immunohistochemical analyses of this case series of
rituximab refractory CBCL suggest that upregulation of bcl-2 may play a major role in therapy resistance.
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Primary cutaneous B-cell lymphomas (CBCLs) generally show an
indolent course. However, recurrences are observed in 25–68% of
the patients (Servitje et al, 2002). For multilocular CBCL, systemic
therapy with rituximab has evolved as an attractive therapeutic
option.
The exact in vivo mechanisms of rituximab still remain elusive
but likely include antibody-dependent cellular cytotoxicity
(ADCC), complement-mediated lysis (CDC) and immune re-
sponses (Reff et al, 1994; Selenko et al, 2001). Furthermore,
rituximab inhibits crucial survival pathways by upregulating the
Raf-kinase inhibitory protein (RKIP), thus directly modifying the
extracellular signal-regulated kinase1/2- and nuclear factor-k B,
respectively (Jazirehi and Bonavida, 2005).
Despite a high initial response rate, local or distant recurrence of
CBCL is frequently observed in rituximab therapy. To delineate
possible factors predicting or being associated with relapse, we
scrutinised recurrent CBCL from four patients before, during and
after systemic rituximab therapy.
PATIENTS AND METHODS
Patient characteristics
Four patients with multifocal CBCL (classified according to the
WHO-EORTC classification for primary cutaneous lymphoma
(Willemze et al, 2005)) were treated with rituximab intravenously
at doses of 375mgm
 2 body surface area at the Department of
Dermatology (University of Wuerzburg, Germany). For patient
characteristics see Table 1. Before therapy and at different time
points after initiation of therapy, skin biopsies were taken to
confirm the diagnosis and to allow further work-up. Patients
provided informed consent before any of these analyses.
Immunohistochemistry
Tissue specimen from cutaneous sites of lymphoma were obtained
by surgical excision, immediately fixed in formalin and embedded
in paraffin. Deparaffinisation, antigen retrieval (s1699, Dako,
Hamburg, Germany), endogenous peroxidase blocking and washing
procedures were performed according to standard protocols. For
staining, slides were incubated for 60min with a murine anti-CD20
polyclonal antibody (Clone L26, Dako), a murine anti-CD3
polyclonal antibody (Clone 17A2, BD, Heidelberg, Germany), Ki-67
(Clone M7240, Dako), a rabbit anti-RKIP polyclonal antibody
(Upstate Biotechnology, Lake Placid, NY, USA) or for 25min with a
murine anti-bcl-2 polyclonal antibody (Clone 124, Dako). Visualisa-
tion was performed with Multi Link Biotin Kit and Streptavidin HRP
(K0690) and Vector Nova Red (Vector SK-4800, Linaris, Wertheim,
Germany) according to the manufacturers’ protocol. Evaluation was
performed by two independent histologists.
RESULTS
To this end, we analysed the presence of CD20 expression itself, as
well as that of major intracellular downstream targets of rituximab
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sby immunohistochemistry. We refrained from quantitative PCR
analyses to avoid data confounding by the expression profile of
inflammatory bystander cells in B-cell lymphoma infiltrates –
which can be excluded by morphological analysis in immuno-
histochemistry. The quantitative evaluation of RKIP and bcl-2
expression was performed in tumour cell-enriched areas of CBCL,
as determined by CD3 staining for detecting infiltrating T
lymphocytes (Figure 1A).
At the time of first diagnosis, all tumours consisted of
predominantly CD20-positive malignant lymphocytes (Table 2,
Figure 1D). Recurrent disease demonstrated in nearly all patients a
persistent CD20 expression (Figure 1F). A transient minor CD20
downregulation was observed in only one single biopsy (Table 2,
Figure 1E).
The expression of proapoptotic RKIP in tissue specimen of
patients before therapy with rituximab, was detectable only in few
lymphoma cells (Table 2, Figure 1G). However, RKIP was
remarkably upregulated in virtually all relapsed lymphoma
specimen during or after therapy (Figure 1H and I). Indicative
for proapoptotic and antiproliferative properties of upregulated
RKIP, the proliferation status of B-cell lymphoma cells remained
at least constant to slightly reduced under rituximab therapy
(Figure 1B and C).
Bcl-2 expression was detected in all lymphoma specimen before
therapy (Table 2), albeit only with a low to moderate intensity
(Figure 1J). Notably, however, the expression of bcl-2 was
consistently increased in relapsing disease (Figure 1K and L).
DISCUSSION
The observed upregulation of proapoptotic RKIP in situ during
rituximab therapy is likely to represent the direct intracellular
signalling properties of rituximab (Vega et al, 2004; Jazirehi and
Bonavida, 2005). RKIP belongs to the family of the metastasis
suppressor genes, which inhibit cellular proliferation, growth
and metastatic spread and induce apoptosis (Keller et al, 2005).
Nevertheless, we observed rituximab refractory relapse in our
patient cohort despite an overexpression of RKIP.
Different factors may contribute to this therapeutic failure of
CD20-targeted therapies, including CD20 downregulation (Foran
et al, 2001), altered signal transduction pathways (Pommier et al,
2004), circulating CD20 protein (Manshouri et al, 2003), poly-
morphisms in the FcgRIII receptor (Cartron et al, 2002) and an
increase in complement-resistant proteins like CD55 or CD59
(Treon et al, 2001; Manches et al, 2003). The immunohistochem-
ical analysis of the presented case series of relapsing CBCL lesions
revealed an unchanged CD20 expression. In contrast, a highly
increased bcl-2 expression in recurrent lesions was observed, thus
providing an alternative explanation for treatment failure. The
overexpression of proapoptotic factors, eg Mcl-1, bcl-2 or bcl-xL,
has been implicated in cancer development, tumour progression
and therapy resistance of B-cell lymphoproliferative diseases
(Bannerji et al, 2003). The regulation of bcl-2 expression underlies
a complex network of environmental stimuli, combined with
altered signal transduction in lymphoma cells – which may
abrogate the proapoptotic properties of rituximab and contribute
to the observed therapeutic failure (Pommier et al, 2004).
Interestingly, the relapsed CBCL in our patient cohort responded
to other subsequent treatment modalities despite upregulation of
bcl-2. Sensitisation to subsequent therapy may be conveyed by a
counteracting downregulation of other antiapoptotic proteins by
rituximab signalling; in this context, the observed increased
expression of RKIP may be of importance, as it also functions as
a negative regulator of antiapoptotic bcl-xL (Vega et al, 2004;
Jazirehi and Bonavida, 2005). Hence, a complex network of
interacting regulators of apoptosis is likely to be influenced by
rituximab and the balance between pro- and antiapoptotic factors
may determine the clinical outcome.
In summary, our results – albeit confined to a limited number
of patients and the analysis of only two pro- or antiapoptotic
signalling pathways, namely RKIP and bcl-2 – raise the hypothesis
that the modulation of regulators of apoptosis may be important
for the clinical effect of rituximab on CBCL. A more complex
analysis of different signalling pathways, which includes potential
cross-talks among apoptosis-regulating proteins in a larger patient
cohort and parallel in vitro experiments, is warranted to establish
the exact modus operandi of rituximab besides CDC and ADCC.
Table 1 Patient characteristics of four patients exhibiting relapse under
therapy with intravenous rituximab 375mgm
 2 of body surface area
Patients 4
Gender
Male 1
Female 3
Age (years) Mean: 6776
Range: 68–72
Prior therapy
Excision 1
Radiotherapy 1
Oral antibiotics 1
Local steroids 1
Other 1
None 0
Concomitant therapy
Excision 4
Radiotherapy 1
Chemotherapy 1
Other 0
None 0
Subsequent therapy
Excision 3
Radiotherapy 2
Chemotherapy 1
Intralesional rituximab 1
Other 1
None 0
Histology of primary diagnosis
FBCL 2
LBCL 2
Best response to rituximab
CR 3
PR 1
SD 0
PD 0
Time to relapse (months) Mean: 978
Range: 0–24
Best response to following therapy
CR 3
PR 0
SD 0
PD 0
Follow-up (years) 271
Current status
Alive with disease 1
Alive without disease 3
Died of lymphoma 0
Died of unrelated cause 0
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Figure 1 (A) CD3þ infiltrating T-lymphocytes surrounding the follicular CBCL lesion. Magnification  10. (B and C) Proliferation status of the tumour
cells as determined by ki-67 staining before (B) and during (C) therapy with rituximab. Magnification  20. (D–F) Expression status of CD20 in relapsed
CBCL before (D) and during (E and F) rituximab treatment. Magnification  40. (G–I) RKIP expression at primary diagnosis (G) and during (H and I)
therapy with rituximab. Magnification  40. (J–L) Expression of antiapoptotic bcl-2 in recurring CBCL at diagnosis (J) and during rituximab application
(K and L). Magnification  40.
Table 2 CD20, RKIP and bcl-2 expression levels in specimen of cutaneous lymphoma relapse obtained at different time points since treatment start
CD20-positive cells (%) RKIP-positive cells (%) Bcl-2-positive cells (%)
Patients Timepoint of biopsy o10 10–30 30–60 60–90 490 o10 10–30 30–60 60–90 490 o10 10–30 30–60 60–90 490
Patient 1 At diagnosis x x x
At relapse after 4 months (during therapy) x x x
At relapse after 6 months (during therapy) x x x
At relapse after 12 months (during therapy) x x x
Patient 2 At diagnosis x x x
At relapse after 6 months
(5 months since therapy cessation)
xx x
At relapse after 9 months
(8 months since therapy cessation)
xx x
Patient 3 At diagnosis x x x
At relapse after 13 months
(6 months since therapy cessation)
xx x
Patient 4 At relapse after 4 months
(2 months since therapy cessation)
xx x
At relapse after 30 months
(28 months since therapy cessation)
xx x
RKIP¼Raf-kinase inhibitory protein. Repetitive biopsies were obtained either during (patient 1) or after (patients 2–4) rituximab therapy.
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